Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nu-Med PlusNUMD Debt-to-Equity is -0.78 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 705 Medical Devices & Instruments companies, Nu-Med Plus ranks worse than 141843.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nu-Med Plus's Debt-to-Equity or its related term are showing as below:
NUMD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -11.76 Med: -0.59 Max: 7.38
Current: -0.78
During the past 13 years, the highest Debt-to-Equity Ratio of Nu-Med Plus was 7.38. The lowest was -11.76. And the median was -0.59.
NUMD's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs NUMD: -0.78
Nu-Med Plus (OTCPK:NUMD) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nu-Med Plus Debt-to-Equity Related Terms
Nu-Med Plus Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nu-Med Plus's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUMD vs SSKN, ODYY, NUWE: Debt-to-Equity Comparison
For the Medical Devices subindustry, Nu-Med Plus's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus (NUMD) has a Debt-to-Equity of -0.78 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nu-Med Plus and its competitors. According to the industry distribution chart, Nu-Med Plus ranks #999999 out of 705 companies in the Medical Devices & Instruments industry.
Is Nu-Med Plus' Debt-to-Equity too high?
Nu-Med Plus' current Debt-to-Equity is -0.78. Based on the distribution chart, Nu-Med Plus ranks #999999 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Nu-Med Plus' Debt-to-Equity compare to SSKN and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nu-Med Plus ranks #999999 out of 705 companies for Debt-to-Equity. This places Nu-Med Plus in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nu-Med Plus and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nu-Med Plus's current Debt-to-Equity is -0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nu-Med Plus stock overvalued right now?
Nu-Med Plus (NUMD) has a current Debt-to-Equity of -0.78. The current Debt-to-Equity is -0.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nu-Med Plus (NUMD), the current Debt-to-Equity is -0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world. It is currently working to locate a merger partner that will be able to fund the final development of these products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUMD has been successfully added to your 
